Diagnostic and therapeutic evaluation of folate-targeted paclitaxel and vinorelbine encapsulating theranostic liposomes for non-small cell lung cancer

Karpuz, Merve; Silindir-Gunay, Mine; Özer, A. Yekta; Öztürk, Süleyman Can; Yanık, Hamdullah; Tuncel, Murat; Aydın, Çisel; Esendağlı, Güneş

doi:10.1016/j.ejps.2020.105576

Cited by 43 publications

(24 citation statements)

References 39 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Furthermore, Karpuz and associates 2020, investigated the in vivo therapeutic prospect and contrasting efficacy of paclitaxel and vinorelbine loaded, Tc-99m radiolabeled, folate targeted nanosized liposomes [50]. The study outcomes demonstrated targeted delivery of chemotherapeutic agents, which got efficiently lodged in tumor vasculature and resided there for a prolonged time, causing substantial reduction of tumor growth.…”

Section: Liposomesmentioning

confidence: 99%

Recent Progress in Lipid Nanoparticles for Cancer Theranostics: Opportunity and Challenges

et al. 2021

View full text Add to dashboard Cite

Cancer is one of the major leading causes of mortality in the world. The implication of nanotherapeutics in cancer has garnered splendid attention owing to their capability to efficiently address various difficulties associated with conventional drug delivery systems such as non-specific biodistribution, poor efficacy, and the possibility of occurrence of multi-drug resistance. Amongst a plethora of nanocarriers for drugs, this review emphasized lipidic nanocarrier systems for delivering anticancer therapeutics because of their biocompatibility, safety, high drug loading and capability to simultaneously carrying imaging agent and ligands as well. Furthermore, to date, the lack of interaction between diagnosis and treatment has hampered the efforts of the nanotherapeutic approach alone to deal with cancer effectively. Therefore, a novel paradigm with concomitant imaging (with contrasting agents), targeting (with biomarkers), and anticancer agent being delivered in one lipidic nanocarrier system (as cancer theranostics) seems to be very promising in overcoming various hurdles in effective cancer treatment. The major obstacles that are supposed to be addressed by employing lipidic theranostic nanomedicine include nanomedicine reach to tumor cells, drug internalization in cancer cells for therapeutic intervention, off-site drug distribution, and uptake via the host immune system. A comprehensive account of recent research updates in the field of lipidic nanocarrier loaded with therapeutic and diagnostic agents is covered in the present article. Nevertheless, there are notable hurdles in the clinical translation of the lipidic theranostic nanomedicines, which are also highlighted in the present review along with plausible countermeasures.

show abstract

Section: Liposomesmentioning

confidence: 99%

Recent Progress in Lipid Nanoparticles for Cancer Theranostics: Opportunity and Challenges

et al. 2021

View full text Add to dashboard Cite

show abstract

“…Having a great potential for diagnosis and therapy, these FR-targeted systems could be advantageous to nanotheranostic applications. Currently, FA-based theranostic systems are widely explored in both in vitro and in vivo investigations focusing on better treatments for cancer [ 32 , 36 , 37 , 38 , 39 ].…”

Section: Introductionmentioning

confidence: 99%

Highly Sensitive Electrochemical Biosensor Using Folic Acid-Modified Reduced Graphene Oxide for the Detection of Cancer Biomarker

et al. 2021

View full text Add to dashboard Cite

The detection of cancer biomarkers in the early stages could prevent cancer-related deaths significantly. Nanomaterials combined with biomolecules are extensively used in drug delivery, imaging, and sensing applications by targeting the overexpressed cancer proteins such as folate receptors (FRs) to control the disease by providing earlier treatments. In this investigation, biocompatible reduced graphene oxide (rGO) nanosheets combined with folic acid (FA)-a vitamin with high bioaffinity to FRs-is utilized to develop an electrochemical sensor for cancer detection. To mimic the cancer cell environment, FR-β protein is used to evaluate the response of the rGO-FA sensor. The formation of the rGO-FA nanocomposite was confirmed through various characterization techniques. A glassy carbon (GC) electrode was then modified with the obtained rGO-FA and analyzed via differential pulse voltammetry (DPV) for its specific detection towards FRs. Using the DPV technique, the rGO-FA-modified electrode exhibited a limit of detection (LOD) of 1.69 pM, determined in a linear concentration range from 6 to 100 pM. This excellent electrochemical performance towards FRs detection could provide a significant contribution towards future cancer diagnosis. Moreover, the rGO-FA sensing platform also showed excellent specificity and reliability when tested against similar interfering biomolecules. This rGO-FA sensor offers a great promise to the future medical industry through its highly sensitive detection towards FRs in a fast, reliable, and economical way.

show abstract

“…Thus, active targeting nanosystems are more efficient than passive targeting ones. Active targeting is possible exclusively when the nanocarriers are enriched with ligands that are specific for the overexpressed receptors in lung cancers [26]. This phenomenon enhances the binding capacity of the drug and imaging modalities to the tumor tissues and thus increases the drug entrapment capacity at the tumor site.…”

Section: Introductionmentioning

confidence: 99%

“…A strong ligand/receptor binding affinity serves as role model to promote active binding technology. This can improve the targeted delivery of theranostics and therapeutic agents on the one hand and overcome the problems allied with conventional approaches on the other hand [26]. The visual illustration of various nanotechnology-based theranostic delivery approaches are shown in Figure 1.…”

Section: Introductionmentioning

confidence: 99%

Onco-Receptors Targeting in Lung Cancer via Application of Surface-Modified and Hybrid Nanoparticles: A Cross-Disciplinary Review

et al. 2021

View full text Add to dashboard Cite

Lung cancer is among the most prevalent and leading causes of death worldwide. The major reason for high mortality is the late diagnosis of the disease, and in most cases, lung cancer is diagnosed at fourth stage in which the cancer has metastasized to almost all vital organs. The other reason for higher mortality is the uptake of the chemotherapeutic agents by the healthy cells, which in turn increases the chances of cytotoxicity to the healthy body cells. The complex pathophysiology of lung cancer provides various pathways to target the cancerous cells. In this regard, upregulated onco-receptors on the cell surface of tumor including epidermal growth factor receptor (EGFR), integrins, transferrin receptor (TFR), folate receptor (FR), cluster of differentiation 44 (CD44) receptor, etc. could be exploited for the inhibition of pathways and tumor-specific drug targeting. Further, cancer borne immunological targets like T-lymphocytes, myeloid-derived suppressor cells (MDSCs), tumor-associated macrophages (TAMs), and dendritic cells could serve as a target site to modulate tumor activity through targeting various surface-expressed receptors or interfering with immune cell-specific pathways. Hence, novel approaches are required for both the diagnosis and treatment of lung cancers. In this context, several researchers have employed various targeted delivery approaches to overcome the problems allied with the conventional diagnosis of and therapy methods used against lung cancer. Nanoparticles are cell nonspecific in biological systems, and may cause unwanted deleterious effects in the body. Therefore, nanodrug delivery systems (NDDSs) need further advancement to overcome the problem of toxicity in the treatment of lung cancer. Moreover, the route of nanomedicines’ delivery to lungs plays a vital role in localizing the drug concentration to target the lung cancer. Surface-modified nanoparticles and hybrid nanoparticles have a wide range of applications in the field of theranostics. This cross-disciplinary review summarizes the current knowledge of the pathways implicated in the different classes of lung cancer with an emphasis on the clinical implications of the increasing number of actionable molecular targets. Furthermore, it focuses specifically on the significance and emerging role of surface functionalized and hybrid nanomaterials as drug delivery systems through citing recent examples targeted at lung cancer treatment.

show abstract

Diagnostic and therapeutic evaluation of folate-targeted paclitaxel and vinorelbine encapsulating theranostic liposomes for non-small cell lung cancer

Cited by 43 publications

References 39 publications

Recent Progress in Lipid Nanoparticles for Cancer Theranostics: Opportunity and Challenges

Recent Progress in Lipid Nanoparticles for Cancer Theranostics: Opportunity and Challenges

Highly Sensitive Electrochemical Biosensor Using Folic Acid-Modified Reduced Graphene Oxide for the Detection of Cancer Biomarker

Onco-Receptors Targeting in Lung Cancer via Application of Surface-Modified and Hybrid Nanoparticles: A Cross-Disciplinary Review

Contact Info

Product

Resources

About